Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352239 | 1.00 | CPB2 (0.40) | CPB2MAPTUSP2CYP3A4ALDH1A1 | |
| SCHEMBL7227733 | 0.99 | CPB2 (0.40) | CPB2MAPTUSP2CYP3A4ALDH1A1 | |
| SCHEMBL7227018 | 0.99 | CPB2 (0.40) | CPB2MAPTUSP2CYP3A4ALDH1A1 | |
| SCHEMBL7227828 | 0.99 | CPB2 (0.40) | CPB2MAPTUSP2CYP3A4ALDH1A1 | |
| SCHEMBL5353262 | 0.99 | CPB2 (0.40) | CPB2MAPTUSP2CYP3A4ALDH1A1 | |
| SCHEMBL7227146 | 0.99 | CPB2 (0.40) | CPB2MAPTUSP2CYP3A4ALDH1A1 | |
| SCHEMBL7234586 | 0.99 | CPB2 (0.40) | CPB2MAPTUSP2CYP3A4ALDH1A1 | |
| SCHEMBL5350121 | 0.91 | CPB2 (0.38) | CPB2MAPTUSP2CYP3A4ALDH1A1 | |
| SCHEMBL5354157 | 0.91 | CPB2 (0.38) | CPB2MAPTUSP2CYP3A4ALDH1A1 | |
| SCHEMBL7227354 | 0.90 | CPB2 (0.37) | CPB2MAPTUSP2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196081-B2 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050192449-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-01 | — | — | US | disclosed |
| US-6737417-B2 | AN ANTIESTROGENIC AGENT CONTAININING AROMATIC OR HETEROAROMATIC COMPOUNDS CONTAINING HYDROXYCARBONYL OR METAL SALT- HALOGENOALKYL SIDE CHAIN; USEFUL FOR TREATING BREAST CANCER | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-18 | — | — | US | disclosed |
| EP-1361205-A1 | Compounds with hydroxycarbonyl-halogenalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-12 | — | — | EP | disclosed |
| US-6610733-B2 | Antiestrogen, therapeutic agent for breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20030130347-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-10 | — | — | US | disclosed |
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-03 | — | — | US | disclosed |
| US-20030114524-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chain | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-06-19 | — | — | US | disclosed |
| US-20030092695-A1 | Metal salts of 3-methyl-chromane or thiochromane derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-15 | — | — | US | disclosed |
| US-6552068-B1 | Having anti-estrogenic activity; for use in therapy | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-1240155-A4 | METAL SALTS OF 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-04-16 | — | — | EP | disclosed |
| EP-1241167-A1 | 3-ETHYL-, 3-PROPYL- OR 3-BUTYL-CHROMAN AND -THIOCHROMAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
| EP-1241158-A1 | COMPOUND HAVING HYDROXYCARBONYL-HALOGENOALKYL SIDE CHAIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
| EP-1241165-A1 | OPTICALLY ACTIVE CHROMAN AND THIOCHROMAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
| EP-1240155-A1 | METAL SALTS OF 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001042236-A1 | METAL SALTS OF 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | NR5A1, CYP19A1, SHBG | CPB2 3026/4885MAPT 2959/4885USP2 3858/4885 |
| US-20050192449-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CYP19A1, HSD17B11, SHBG | CPB2 2517/4885MAPT 4418/4885USP2 2521/4885 |
| US-20030092695-A1 | Metal salts of 3-methyl-chromane or thiochromane derivatives | NR5A1, SHBG, ESR1 | CPB2 3086/4885MAPT 1736/4885USP2 3184/4885 |
| US-20030114524-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chain | HSD17B11, CYP19A1, SHBG | CPB2 2842/4885MAPT 4629/4885USP2 2284/4885 |
| US-20030130347-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | HSD17B11, CYP19A1, SHBG | CPB2 2857/4885MAPT 4620/4885USP2 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.